Precision BioSciences Reports Third Quarter 2023 Financial R

- Precision to present late breaker PBGENE-HBV data at The Liver Meeting of AASLD in November 2023


- Hosted R&D Day highlighting exclusive focus on in vivo gene editing pipeline


- Expanded...

Related Keywords

Belgium , Brussels , Bruxelles Capitale , Michael Amoroso , Eli Lilly , Exchange Commission , Mitochondrial Elimination Program , Novartis , Development Expenses , Viral Elimination Program , Nasdaq , European Society Of Gene Cell Therapy , University Of Pennsylvania Gene Therapy Program , Gene Insertion Program , Trademark Office , Gene Excision Program , Imugene Limited , Precision Biosciences Inc , Single Platform Company , Precision Biosciences , Chief Executive Officer , Strategic Transaction , Single Platform Company Focused , Vivo Gene , European Society , Cell Therapy , American Association , Liver Diseases , Annual Meeting , Mutant Mitochondrial Elimination Program , Gene Therapy Program , Prevail Therapeutics , Ended September , Cash Equivalents , Novartis Agreement , Administrative Expenses , Private Securities Litigation Reform Act , Quarterly Report , Three Months Ended September , Markets ,